Medication Anxiety Disorders

Question: Discuss about theMedicationfor Anxiety Disorders. Answer: Alprax 1 Alprax 1 contains the active ingredient Alprazolam 1 mg which is a benzodiazepine that affects to stabilize the chemicals in the brain which gets unbalanced in the patients suffering from anxiety disorders, anxiety out of depression and panic disorders. Several regulatory guidelines are present in the Australian territories for regulating the usage and sell of the medication in the country. Some of the binding and non-binding instruments that are followed in the regulation of Alprax are Therapeutic Goods Act, British Pharmacopoeia and other national and international regulatory guidelines. This assignment will discuss these binding and non-binding instruments in details depicting the controls that are exercised related to Alprax in Australia. The first binding instrument is the Therapeutic Goods Act (1989) that lays down several conditions that are applicable to the relevant class and category of the therapeutic goods according to the act for Alprax. The instrument mentions the product details, warnings, standard and specific indications that have to be observed prior to prescribing the medication to the patients to avoid adverse drug reactions and dependence (1). The Therapeutic Goods Administration (TGA) of Australia controls the regulatory formalities pertaining to the act and monitors the bindings by issuing public notices and making it compulsory for the manufacturers to supply the Consumer Medicine Information (CMI) along with the product pack. The second binding instrument is the Standard for the Uniform Scheduling of Medicines and Poisons where Alprax or Alprazolam has been up-scheduled from Schedule 4 to Schedule 8 for controlling the illicit usage of the medication in the country that causes dependence among the users. This up-scheduling occurred on 01st February 2014 by an authority of the MOH (Ministry of Health) of NSW (New South Wales) that bound the prescription rules for Alprax to the drug dependent and non-drug dependent persons (2). This up-scheduling is applicable for all the preparations of the medication. A non-binding instrument for Alprax 1 is the prescribing guideline set by Department of Health and Human Services of the Tasmanian government that has been approved by The Royal Australian and New Zealand College of Psychiatrists and The Royal Australian College of General Practitioners for Alprazolam. This guideline provides a general introduction to the medication that is followed by a detailed account of the risks associated with the mixing of the opioid and Alprazolam combination and its various effects on the central nervous system followed by the warning for avoiding such mixes. This combination increases the effects of Alprax that leads to several major clinical issues. Information has also been provided for its use in case of panic disorder and its abuse. Finally, the legal requirements have been enlisted that are required for prescribing Alprax 1. Alprax is known to be highly addictive that have proved criminal consequences for the user that might eventually lead to his death (4). To avoid such mishaps, the Australian government has laid down the binding and non-binding instruments for controlling the prescription and usage of the medication in the country. References Federal Register of Legislation - Australian Government [Internet]. Legislation.gov.au. 2016 [cited 20 October 2016]. Available from: https://www.legislation.gov.au/Series/C2004A03952 The Poisons Standard (the SUSMP) [Internet]. Therapeutic Goods Administration (TGA). 2016 [cited 20 October 2016]. Available from: https://www.tga.gov.au/publication/poisons-standard-susmp Department of Health and Human Services [Internet]. Dhhs.tas.gov.au. 2016 [cited 20 October 2016]. Available from: https://www.dhhs.tas.gov.au/ Granoff AL. The Impact of Benzodiazepine Management in the Randomized, Double-Blind Evaluation of d-Cycloserine or Alprazolam Combined With Virtual Reality Exposure Therapy. American Journal of Psychiatry. 2014 Nov 1.